ZAI LAB LIMITED Total Liabilities
ZAI LAB LIMITED (ZLAB) had Total Liabilities of $467.76 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities
us-gaap:Liabilities · last filed 2026-08-06
- 2026-06-30: Liabilities $467.76M.
- 2026-03-31: Liabilities $433.76M.
- 2025-12-31: Liabilities $456.88M.
- 2025-09-30: Liabilities $399.00M.
| Period end | Liabilities | Liabilities as first filed |
|---|---|---|
| 2026-06-30 | $467.76M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $433.76M 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $456.88M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $399.00M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $372.37M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $362.58M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | $344.86M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $317.68M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $283.19M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $226.27M 10-Q · filed 2024-05-08 | |
| 2023-12-31 | $240.18M 10-K · filed 2025-02-27 | |
| 2023-09-30 | $162.72M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $174.06M 10-Q · filed 2023-08-07 | |
| 2023-03-31 | $168.83M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $174.54M 10-K · filed 2024-02-27 | |
| 2022-09-30 | $192.65M 10-Q · filed 2022-11-09 | |
| 2022-06-30 | $206.61M 10-Q · filed 2022-08-09 | |
| 2022-03-31 | $192.91M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $230.00M 10-K · filed 2023-03-01 | |
| 2021-09-30 | $140.15M 10-Q · filed 2021-11-09 | |
| 2021-06-30 | $223.52M 10-Q · filed 2021-08-09 | |
| 2021-03-31 | $121.62M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $128.29M 10-K · filed 2022-03-01 | |
| 2020-06-30 | $82.75M 6-K · filed 2020-09-11 | |
| 2019-12-31 | $60.49M 10-K · filed 2021-03-01 | |
| 2019-09-30 | $54.52M 6-K · filed 2020-01-21 | |
| 2018-12-31 | $50.91M 20-F · filed 2020-04-29 | $50.91M 20-F · filed 2019-03-29 |
| 2017-12-31 | $14.46M 20-F · filed 2019-03-29 | |
| 2016-12-31 | $5.95M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |